Table 5.
Incidence rate of thromboembolic events
| Overall (n = 6286) | Apixaban initiators (n = 3093) | From warfarin (n = 2034) | From other NOACs (n = 1118) | P value for trenda | |
|---|---|---|---|---|---|
| Ischemic stroke/SE/TIA | 89 (1.00) | 42 (1.01) | 33 (1.05) | 13 (0.80) | 0.686 |
| Ischemic stroke | 79 (0.88) | 36 (0.87) | 30 (0.96) | 12 (0.74) | 0.717 |
| Atherothrombotic | 8 (0.09) | 6 (0.14) | 2 (0.06) | 0 (0) | NA |
| Cardioembolic | 45 (0.50) | 19 (0.46) | 17 (0.54) | 8 (0.49) | 0.836 |
| Lacunar | 7 (0.08) | 5 (0.12) | 0 (0) | 2 (0.12) | NA |
| Cryptogenic | 9 (0.10) | 4 (0.10) | 4 (0.13) | 1 (0.06) | NA |
| Unknown | 6 (0.07) | 2 (0.05) | 3 (0.10) | 1 (0.06) | NA |
| Others | 5 (0.06) | 1 (0.02) | 4 (0.13) | 0 (0) | NA |
| SE | 3 (0.03) | 2 (0.05) | 0 (0) | 1 (0.06) | NA |
| TIA | 8 (0.09) | 4 (0.10) | 4 (0.13) | 0 (0) | NA |
Note: Number of patients (% per year).
Abbreviations: NA, not assessed due to lower event rates; NOACs, non‐vitamin K oral anticoagulants; SE, systemic embolism; TIA, transient ischemic attack.
a
Comparison among three subgroups.